Food News and Research

RSS

Chocolate can lower blood pressure and reduce risk of heart disease: Study

Easter eggs and other chocolate may be good for you - at least in small quantities and preferably if it's dark chocolate - according to research that shows just one small square of chocolate a day can lower your blood pressure and reduce your risk of heart disease. The study is published online today (Wednesday 31 March) in the European Heart Journal.

30 Mar 2010

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.

30 Mar 2010

BRIC ministers reach agreement on promoting global food security

Brazil, Russia, India and China, collectively known as BRIC, have reached an agreement to promote global food security, the Moscow Times reports (Anishyuk, 3/29).

30 Mar 2010

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

30 Mar 2010

Rite Aid, AAAAI team up to offer guides to allergy sufferers

Rite Aid and the American Academy of Allergy, Asthma & Immunology are again teaming up this spring to help allergy sufferers with free allergy guides available now in nearly 4,800 Rite Aid stores nationwide and online at www.riteaid.com.

30 Mar 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010

Woman sentenced in Michigan Medicare fraud case; Medicaid fraud alleged in NY dental clinics

Profits came quickly: Over one year, Daisy Martinez ripped off Medicare for $10.7 million at three clinics, and her daughter got $649,000 in just four months as they billed the government for sham drug treatments while luring desperate people off the street with cash, food and painkillers.

30 Mar 2010

Cangene extends botulism antitoxin contract with BARDA

Cangene Corporation today reports that it has signed a no-cost modification to extend its botulism antitoxin contract with the Biomedical Advanced Research and Development Authority ("BARDA"). BARDA is the department within the U.S. Department of Health and Human Services that manages the two biodefence-related, stockpiling contracts Cangene has with HHS.

30 Mar 2010

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

29 Mar 2010

Unrestricted availability of food can trigger overconsumption and obesity

Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

29 Mar 2010

FDA grants SynCardia Systems conditional approval to conduct IDE study of Freedom driver system

SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom™ driver system, the first-ever U.S. portable driver designed to power SynCardia's Total Artificial Heart.

29 Mar 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

Neogen's third-quarter fiscal 2010 revenues up 21%

Neogen Corporation announced today that its net income for the third quarter of FY 2010, which ended Feb. 28, increased 38% from the previous year to $3,881,000. Adjusted for a 3-for-2 stock split effective Dec. 15, net income in the quarter rose to $0.17 per share, compared to the prior year's $0.12.

29 Mar 2010

FDA grants IDE approval for Urovalve's Surinate Bladder Management System

Urovalve, a medical device company focused on creating superior products for urinary flow and control, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for the Company's Surinate® Bladder Management System, allowing Urovalve to conduct a clinical study for the Company's lead device in the United States.

29 Mar 2010

China Medicine's 2009 revenues up 20.7%

China Medicine Corporation, primarily a manufacturer, leading distributor and developer of Western pharmaceuticals, traditional Chinese medicines, and other nutraceuticals, today announced its fourth quarter and full year 2009 results.

29 Mar 2010

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta Incorporated today reported results for the quarter and year ended December 31, 2009. The Company also provided an overview of recent corporate highlights and anticipated milestones.

29 Mar 2010

GEA Niro selects engineering simulation software from ANSYS

GEA Niro has selected engineering simulation software from ANSYS to optimize equipment design and reduce development time and costs. Based in Denmark, GEA Niro is a world market leader in drying technology for the dairy, food, pharmaceutical and chemical industries and is a core technology center in the GEA Process Engineering business segment in GEA Group.

29 Mar 2010

Redpoint Bio announces revenue of $1.9M for full-year 2009

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2009.

29 Mar 2010